D. E. Shaw & Co. Inc. Sells 387,055 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

D. E. Shaw & Co. Inc. lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 68.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 180,676 shares of the company's stock after selling 387,055 shares during the period. D. E. Shaw & Co. Inc. owned 0.21% of IDEAYA Biosciences worth $4,643,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Deutsche Bank AG increased its holdings in IDEAYA Biosciences by 6.9% in the fourth quarter. Deutsche Bank AG now owns 372,979 shares of the company's stock worth $9,586,000 after buying an additional 24,205 shares during the last quarter. DAFNA Capital Management LLC increased its holdings in IDEAYA Biosciences by 5.8% in the fourth quarter. DAFNA Capital Management LLC now owns 498,827 shares of the company's stock worth $12,820,000 after buying an additional 27,417 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in IDEAYA Biosciences by 5.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after buying an additional 142,000 shares during the last quarter. Crestline Management LP increased its holdings in IDEAYA Biosciences by 283.9% in the fourth quarter. Crestline Management LP now owns 95,428 shares of the company's stock worth $2,452,000 after buying an additional 70,571 shares during the last quarter. Finally, Brevan Howard Capital Management LP increased its holdings in IDEAYA Biosciences by 210.9% in the fourth quarter. Brevan Howard Capital Management LP now owns 44,539 shares of the company's stock worth $1,145,000 after buying an additional 30,213 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

Analyst Ratings Changes

IDYA has been the topic of a number of research reports. Stephens restated an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $54.27.

IDEAYA Biosciences Stock Up 0.7%

IDYA stock traded up $0.14 during midday trading on Friday, hitting $18.82. 1,046,582 shares of the company traded hands, compared to its average volume of 1,007,688. The business has a 50 day simple moving average of $17.65 and a 200-day simple moving average of $21.92. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -5.70 and a beta of 0.26. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the business posted ($0.53) EPS. Equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.